KORU Medical Systems

KRMD on Nasdaq. KORU Medical Systems sells infusion systems and supplies to domestic, international, and biopharmaceutical customers. Market value $160m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-0.3%low

For every $100 of what the whole company costs, it produced $-0.28 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$3.19 a share, 12% above its 1-year low

Over the past year the price has ranged from $2.86 to $6.61.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.0
-0.0
-0.0
2021202220232024202512 monthsto Sep '26
Revenue
$23m$28m$29m$34m$41m
Operating margin
-29.9%-38.6%-36.0%-19.2%-7.2%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.05bn0.05bn0.05bn0.05bn0.04bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)3 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsStrong, 11.2% a year
  • Buying back its own sharesYes, 4% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $12 million last quarter, up 11% on a year ago.
  • Profit: $218,103, after a loss of $777,966 a year ago.
  • It loses 1 cents on each $1 of sales, compared with 10 cents a year earlier.
  • Over the past 12 months it spent $387,369 more cash than it brought in, compared with $173,904 a year earlier.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$9m
March 2025$10m
June 2025$10m
September 2025$10m
December 2025$11m
March 2026$12m
June 2026$12m
September 2026$12m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$2m
March 2025-$1m
June 2025-$206,867
September 2025-$777,966
December 2025-$486,856
March 2026-$807,078
June 2026$252,449
September 2026$218,103

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
12 March 2026
Next quarterly (estimated, 10-Q)
9 February 2027

Who owns it

None of the long-term investors we follow own it. 85 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

  • Joseph M. Manko, Jr.
    Passive investor
    at least 12.6%−1.4 pts
    (filed with 3 related holders)
    Since 13 February 2026
    What they said

    The Reporting Persons acquired the shares of Common Stock for investment purposes. The purpose of this Amendment No. 12 is to disclose changes in the beneficial ownership of the shares of Common Stock held by the Reporting Persons including: (i) the issuance of shares of Common…

    Read the filing
  • at least 9.9%+1.4 pts
    (filed with 2 related holders)
    Since 30 September 2026
  • Mathew P. Arens
    Passive investor
    at least 6.6%−1.7 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • BlackRock, Inc.
    Passive investor
    5.6%+0.7 pts
    Since 30 June 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 5 insiders bought $246,284 of shares on the open market.

  • Schiller Eric
    Chief Technology Officer
    Bought
    Date
    13 November 2026
    Shares
    8,546
    Price
    $3.63
    Value
    $31,022
  • KALBERMATTEN ADAM R
    Chief Commercial Officer
    Bought
    Date
    8 September 2026
    Shares
    32,000
    Price
    $3.16
    Value
    $101,120
  • KALBERMATTEN ADAM R
    President-Chief Commercial Off
    Bought
    Date
    11 June 2026
    Shares
    12,500
    Price
    $3.94
    Value
    $49,275
  • Schiller Eric
    Chief Technology Officer
    Bought
    Date
    18 May 2026
    Shares
    5,000
    Price
    $3.91
    Value
    $19,550
  • Tharby Linda M
    Chief Executive Officer, Director
    Bought
    Date
    15 May 2026
    Shares
    1,191
    Price
    $3.92
    Value
    $4,669
  • Pazdan Christopher
    Chief Operating Officer
    Bought
    Date
    14 May 2026
    Shares
    5,000
    Price
    $3.88
    Value
    $19,400
  • Adams Thomas Edward
    Chief Financial Officer
    Bought
    Date
    14 May 2026
    Shares
    5,500
    Price
    $3.86
    Value
    $21,248

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 8 later 8-Ks.

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 29% last year. Losing that customer would hurt.

    “As of December 31, 2025, these nine distributors comprised approximately 77% of our net revenues with one U.S. distributor contributing 29%.”

    From the 10-K filed 12 March 2026, Item 1A. Risk Factors. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.